

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**REQUEST FOR REVIEW OF  
THE LISTING COMMITTEE'S DECISION  
TO SUSPEND TRADING IN THE COMPANY'S SHARES**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**” together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 18 December 2021, 29 December 2021 and 30 March 2022 (the “**Announcements**”) in relation to (i) the decision of the Stock Exchange that the Company has failed to maintain a sufficient level of operations as required under Rule 13.24 of the Listing Rules; (ii) the Company's written request for the review of the decision of the Listing Division by the Listing Committee of the Stock Exchange (the “**Listing Committee**”); and (iii) the decision of the Listing Committee to uphold the decision of the Listing Division to suspend trading in the Company's shares under Rule 6.01(3) of the Listing Rules (the “**LC Decision**”), respectively. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

## SUBMISSION OF REVIEW REQUEST

As disclosed in the Announcement dated 30 March 2022, unless the Company applies for a review of the LC Decision in accordance with its rights under Chapter 2B of the Listing Rules, trading in the Company's shares will be suspended from 9:00 a.m. on 12 April 2022 (i.e. after the expiry of seven business days from the date of the LC Decision).

The Board wishes to inform the Shareholders that the Company is discussing with the professional advisers to make a written request to the Listing Review Committee of the Stock Exchange (the "**Listing Review Committee**") on or before 11 April 2022 for the LC Decision to be referred to the Listing Review Committee for a further and final review (the "**LRC Review**") pursuant to Rule 2B.06(2) of the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules as regards to any updates on the LRC Review.

**Shareholders who have any queries about the implications of the LC Decision are advised to obtain appropriate professional advice. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 4 April 2022

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Li Jiuhua (*Chief Executive Officer*)  
Mr. Li Xiaoshuang  
Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Tam Ho Leung Simon  
Ms. Wang Weixia  
Mr. Chai Nan  
Mr. Lee See Barry

*Non-executive Directors*

Dr. He Yiwu  
Ms. Choi Ngai Wah

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*